96686 ⎘
Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links; Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
Sub-classes:FAP-ACTIVATED PROTEASOME INHIBITORS FOR TREATING SOLID TUMORS
#2TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS
#3GLYCOSIDE DUAL-CLEAVAGE LINKERS FOR ANTIBODY-DRUG CONJUGATES
#4Drug-Conjugates, Conjugation Methods, And Uses Thereof
#5METHODS AND REAGENTS FOR ANALYZING PROTEIN-PROTEIN INTERFACES
#6CELL-PERMEANT INHIBITORS OF VIRAL CYSTEINE PROTEASES
#7NOVEL DEUTERATED CYANO COMPOUNDS, PREPARATION METHODS, COMPOSITIONS AND APPLICATIONS
#8CONJUGATES AND METHODS OF USING THE SAME
#9AMIDE DERIVATIVES OF N-UREA SUBSTITUTED AMINO ACIDS AS FORMYL PEPTIDERECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS
#10COMPOUNDS FOR TAU PROTEIN DEGRADATION
#11TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS
#12RESPIRATORY TREATMENTS
#13SMALL MOLECULE INHIBITORS OF SARS-CoV-2 VIRAL REPLICATION AND USES THEREOF
#14Modulators of programmed death-ligand-1 and/or programmed death-ligand-2
#15Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
#16Cyclic peptide compound simulating natural product structure, and method for preparation thereof
#17Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
#18Glycoside dual-cleavage linkers for antibody-drug conjugates
#19AMIDE DERIVATIVES OF N-UREA SUBSTITUTED AMINO ACIDS AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS
#20Scalable Production of Standardized Extracellular Vesicles, Extracellular Vesicle Preparations and Uses Thereof
#21METHODS AND REAGENTS FOR ANALYZING PROTEIN-PROTEIN INTERFACES
#22FAP-activated proteasome inhibitors for treating solid tumors
#23PYRROLOBENZODIAZEPINE CONJUGATES
#24METHOD OF CONSTRUCTING PROTAC BY USING DOUBLE TARGETS
#25SELECTIVE METAL-MEDIATED ARYLATION OF DICHALCOGENIDES IN BIOMOLECULES
#26Drug-conjugates, conjugation methods, and uses thereof
#27BIOLOGICALLY ACTIVE C-TERMINAL ARGININE-CONTAINING PEPTIDES
#28Conjugates and methods of using the same
#29COMPOUNDS FOR TAU PROTEIN DEGRADATION
#30TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE
#31Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
#32Indole derivatives as estrogen receptor degraders
#33Proteolysis Targeting Chimera Compounds and Methods of Preparing and Using Same
#34FAP-activated proteasome inhibitors for treating solid tumors
#35Methods of producing anamorelin hydrochloride having controlled chloride content
#36MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS
#37N-acyldipeptide derivatives and their uses
#38PPAR agonists and methods of use thereof
#39PRODRUG OF AN ICE INHIBITOR
#40Compounds having estrogen receptor alpha degradation activity and uses thereof
#41Growth Hormone Releasing Peptides
#42Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
#43MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS
#44Fluorohydroxyproline derivatives useful in the preparation of proteolysis targeted chimeras
#45Cytotoxic tubulysin compounds for conjugation
#46Indole derivatives as estrogen receptor degraders
#47Methods of producing anamorelin hydrochloride having controlled chloride content
#48Compounds and their use in treating cancer
#49Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof
#50Tank-binding kinase-1 PROTACs and associated methods of use
#51Dipeptide analogs as TGF-beta inhibitors
#52PAR2 mimetic peptides and uses thereof
#53FAP-activated proteasome inhibitors for treating solid tumors
#54Methods of producing anamorelin hydrochloride having controlled chloride content
#55Scalable production of standardized extracellular vesicles, extracellular vesicle preparations and uses thereof
#56PRODRUG OF AN ICE INHIBITOR
#57PPAR agonists and methods of use thereof
#58Combination of N-acyldipeptide derivatives and retinol, and methods of use thereof
#59Methods and reagents for analyzing protein-protein interfaces
#60Methods and reagents for analyzing protein-protein interfaces
#61Drug-conjugates, conjugation methods, and uses thereof
#62Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
#63STAT6 inhibitors
#64Compounds having estrogen receptor alpha degradation activity and uses thereof
#65Selective cysteine protease inhibitors and uses thereof
#66Pharmaceutical composition for the prevention and treatment of cardiovascular disease comprising the peptide having the ability to inhibit angiotensin-1 converting enzyme as an active ingredient
#67MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS
#68Hepatitis C virus inhibitors
#69Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
#70TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE
#71Derivatives of dolastatin 10 and uses thereof
#72Growth Hormone Releasing Peptides
#73BIOLOGICALLY ACTIVE C-TERMINAL ARGININE-CONTAINING PEPTIDES
#74Tripeptide compound, preparation method therefor, and application thereof
#75Compounds for enzyme inhibition
#76PPAR agonists and methods of use thereof
#77Serine derivatives as ghrelin receptor agonists
#78HCV NS-3 serine protease inhibitors
#79Macrocyclic inhibitors of flaviviridae viruses
#80Process for preparing D-arginyl-2,6-dimethyl-L-tyrosyl-L-lysyl-L-phenylalaninamide
#81Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
#82N-acyldipeptide derivatives and their uses
#83Selective caspase inhibitors and uses thereof
#84Methods and reagents for analyzing protein-protein interfaces
#85Prodrug of an ICE inhibitor
#86NOVEL ULTRASHORT HYDROPHOBIC PEPTIDES THAT SELF-ASSEMBLE INTO NANOFIBROUS HYDROGELS AND THEIR USES
#87Self-assembling peptides, peptidomimetics and peptidic conjugates as building blocks for biofabrication and printing
#88FAP-activated proteasome inhibitors for treating solid tumors
#89Cytotoxic tubulysin compounds for conjugation
#90Tubulysin derivatives
#91BISAMIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR REDUCING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN
#92IAP binding compounds
#93Cyclic peptide compound, and preparation method, pharmaceutical composition and use thereof
#94Protein-polymer complex, TGase substrate-containing polymer, TGase substrate-containing monomer, method for producing protein-polymer complex, and method for improving protein function at solid-liquid interface or in vicinity of solid-liquid interface
#95Methods and intermediates for preparing macrolactams
#96Methods of producing anamorelin hydrochloride having controlled chloride content
#97Methods of producing anamorelin hydrochloride having controlled chloride content
#98Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
#99Methods of producing anamorelin hydrochloride having controlled chloride content
#100Deuterated compounds useful for treating neurodegenerative diseases
#101Method for producing dipeptide derivative containing disubstituted amino acid residue
#102STAT6 inhibitors
#103Tubulysin analogs and methods of making and use
#104Hepatitis C virus inhibitors
#105Estrogen-related receptor alpha based protac compounds and associated methods of use
#106Benzidine derivative, method for preparing same, and pharmaceutical composition containing benzidine derivative for treating liver disease caused by hepatitis C virus
#107PEPTIDE MOLECULAR MATERIALS
#108Compounds for enzyme inhibition
#109Processes for forming amide bonds and compositions related thereto
#110AGENT FOR PREVENTING ARTERIOSCLEROSIS, AGENT FOR SUPPRESSING VASCULAR INTIMAL THICKENING AND AGENT FOR IMPROVING VASCULAR ENDOTHELIAL FUNCTION
#111IAP binding compounds
#112Tubulysin derivatives
#113Prodrug of an ice inhibitor
#114Macrocyclic inhibitors of flaviviridae viruses
#115N-acyldipeptide derivatives and their uses
#116Aldehyde capture ligation technology for synthesis of amide bonds
#117Benzylamine derivatives as inhibitors of plasma kallikrein
#118Synthesis of telaprevir and boceprevir, or pharmaceutically acceptable salts or solvates as well as intermediate products thereof including β-amino acids prepared via Mukaiyama aldol addition
#119Pharmaceutical composition for the prevention and treatment of cardiovascular disease comprising the peptide having the ability to inhibit angiotensin-1 converting enzyme as an active ingredient
#120Pyrrolobenzodiazepines as unsymmetrical dimeric PBD compounds for inclusion in targeted conjugates
#121Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
#122Inhibitors of Furin and other pro-protein convertases
#123Methods of producing anamorelin hydrochloride having controlled chloride content
#124Organogels and emulsions for biological and non-biological applications
#125Modulators of protease activated receptors
#126Growth hormone releasing peptides
#127Macrocyclic compounds for suppressing replication of hepatitis C virus
#128Selective caspase inhibitors and uses thereof
#129Hepatitis C virus inhibitors
#130MICROORGANISM AND METHOD FOR OVERPRODUCTION OF GAMMA-GLUTAMYLCYSTEINE AND DERIVATIVES OF THIS DIPEPTIDE BY FERMENTATION
#131N-acyldipeptide derivatives and their uses
#132FAP-activated proteasome inhibitors for treating solid tumors
#133ANTIBIOTICS AND METHODS FOR MANUFACTURING THE SAME
#134Benzylamine derivatives as inhibitors of plasma kallikrein
#135Macrocyclic heterocyclic compound for inhibiting hepatitis C virus and preparation and use thereof
#136Macrocyclic proline derived HCV serine protease inhibitors
#137MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS
#138Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
#139Compounds for enzyme inhibition
#140Compounds for enzyme inhibition
#141Selective cysteine protease inhibitors and uses thereof
#142Compounds for enzyme inhibition
#143Neuroprotective and neurorestorative methods and compositions
#144Macrocyclic inhibitors of flaviviridae viruses
#145Prodrug of an ice inhibitor
#146Process and intermediates for preparing macrolactams
#147Synthetic ion channels
#148Modulations of protease activated receptors
#149Cysteine protease inhibitors
#150Cyclized peptidomimetic small molecule inhibitors of the WDR5 and MLL1 interaction
#151Growth hormone releasing peptides
#152Sulfur-containing amino acid derivative
#153NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF
#154Compounds for enzyme inhibition
#155Compounds for enzyme inhibition
#156IAP BIR domain binding compounds
#157Compounds for enzyme inhibition
#158C-Met receptor regulation by angiotensin IV (AT4) receptor ligands
#1593,8-diaminotetrahydroquinoline derivative
#160Hepatitis C virus inhibitors
#161DEUTERATED COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISEASES
#162Pyruvamide compounds as inhibitors of dust mite group 1 peptidase allergen and their use
#163Cysteine protease inhibitors
#164Multi-valent poly-Ubl chain inhibitors and methods of use
#165Immunoconjugates, compositions for making them, and methods of making and use
#166Caspase inhibitors
#167Cysteine protease inhibitors
#168Organic compounds and their uses
#169Insulin analogues
#170Enantio- and stereo specific synthesis of β-amino-α-hydroxy amides
#171IAP BIR DOMAIN BINDING COMPOUNDS
#172S-Protected Cysteine Analogs and Related Compounds
#173S-t-butyl protected cysteine di-peptide analogs and related compounds
#174Anti-Viral Compounds
#175Processes for forming amide bonds and compositions related thereto
#176Compounds For Enzyme Inhibition
#177Compounds For Enzyme Inhibition
#178Compounds for enzyme inhibition
#179Macrocyclic proline derived HCV serine protease inhibitors
#180AGENT FOR PREVENTING ARTERIOSCLEROSIS, AGENT FOR SUPPRESSING VASCULAR INTIMAL THICKENING AND AGENT FOR IMPROVING VASCULAR ENDOTHELIAL FUNCTION
#181Neuroprotective and neurorestorative method and compositions
#182Hepatitis C virus inhibitors
#183DIMERIC IAP ANTAGONISTS
#184Prodrug of an ICE inhibitor
#185IAP BINDING COMPOUNDS
#186Dipeptoid prodrugs and the use thereof
#187IAP INHIBITORS
#188Whey Protein Hydrolysate Containing Tryptophan Peptide Consisting of Alpha Lactalbumin and the Use Thereof
#189Preparation of alkenes by mild thermolysis of sulfoxides
#190NEUROTROPHIN MIMETICS AND USES THEREOF
#191IAP BINDING COMPOUNDS
#192Modulators of pharmacokinetic properties of therapeutics
#193Acylation of hindered amines and functionalized bis-peptides obtained thereby
#194Biologically active C-terminal arginine-containing peptides
#195Inhibitors of serine proteases
#196Dimeric small molecule potentiators of apoptosis
#197Casein hydrolyzate, process for producing the same and use thereof
#198Selective caspase inhibitors and uses thereof
#1995-substituted-2-imino-thiazolidinone compounds and their use as inhibitors of bacterial infection
#200Macrocyclic compounds as hepatitis C virus inhibitors
#201Organic compounds and their uses
#2023,8-diaminotetrahydroquinoline derivative
#203BIR domain binding compounds
#204Tertiary amine substituted peptides useful as inhibitors of HCV replication
#205Anti-viral compounds
#206HCV inhibitors
#207DRUG OR FOOD CONTAINING A PEPTIDE
#208SUBSTITUTED 1,2-ETHYLENEDIAMINES, METHODS FOR PREPARING THEM AND USES THEREOF
#209Alkylamino-substituted dicyanopyridines and their amino acid ester prodrugs
#210HCV NS-3 SERINE PROTEASE INHIBITORS
#211Lactams and uses thereof
#212Compounds for enzyme inhibition
#213Compounds for enzyme inhibition
#214HYDRAZIDO-PEPTIDES AS INHIBITORS OF HCV NS3-PROTEASE
#215P1-NONEPIMERIZABLE KETOAMIDE INHIBITORS OF HCV NS3 PROTEASE
#216Peptides Inhibiting Angiotensin-Converting Enzyme
#217HCV NS-3 Serine Protease Inhibitors
#218Substituted 1,2-ethylenediamines, Methods for Preparing Them and Uses Thereof
#219Dimeric small molecule potentiators of apoptosis
#220AGENT FOR PREVENTING ARTERIOSCLEROSIS, AGENT FOR SUPPRESSING VASCULAR INTIMAL THICKENING AND AGENT FOR IMPROVING VASCULAR ENDOTHELIAL FUNCTION
#221Modulators of pharmacokinetic properties of therapeutics
#222Dimeric small molecule potentiators of apoptosis
#223Hepatitis C virus inhibitors
#224Process for producing dipeptides
#225Compounds for enzyme inhibition
#226Heteroaryl-containing tripeptide HCV serine protease inhibitors
#227Peptides for the treatment of HCV infections
#228Amino Acid Derivatives
#229Biologically active C-terminal arginine-containing peptides
#230Anti-cancer compounds
#231IAP binding compounds
#232Non-Natural Amino Acid Derivatives
#233Prodrug of an ICE inhibitor
#234C-Met receptor regulation by angiotensin IV (AT) receptor ligands
#235Growth hormone releasing peptides
#236Novel Drugs for Dementia
#237Amino acid derivatives and pharmaceutical uses thereof
#238Hepatitis C Inhibitor Peptide Analogs
#239Selective inhibitors of neurotensin degrading enzymes
#240Dimeric small molecule potentiators of apoptosis
#241Modulators of pharmacokinetic properties of therapeutics
#242Isoquinoline derivatives as calpain inhibitors
#243Compounds for enzyme inhibition
#244Novel Lactams And Uses Thereof
#245Dimeric IAP inhibitors
#246Casein hydrolyzate, process for producing the same and use thereof
#247Compounds for enzyme inhibition
#248Organic compounds and their uses
#249Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels
#250HCV NS-3 serine protease inhibitors
#251HCV NS-3 serine protease inhibitors
#252Advanced glycation end-product intermediaries and post-amadori inhibition
#253Compounds as inhibitors of hepatitis C virus NS3 serine protease
#254Biogically non-degradable peptides, angiostensin converting enzyme inhibitor, drug and functional food
#255Compounds for enzyme inhibition
#256Anti-inflammatory peptides
#257HCV inhibitors
#258Compounds as inhibitors of hepatitis C virus NS3 serine protease
#259Dipeptide phenyl ethers
#260Compounds as inhibitors of hepatitis C virus NS3 serine protease
#261BIR domain binding compounds
#262Substituted 1,2-ethylenediamines, methods for preparing them and uses thereof
#263Peptide gap junction modulators
#264Pyrane derivatives as both ACE- and NEP-inhibitors
#265Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
#266Anti-cancer compounds
#267Hepatitis C virus inhibitors
#268Pyrrolidin-2-one derivatives as inhibitors of factor xa
#269Pyrrolidin-2-one derivatives as inhibitors of factor xa
#270Synthesis of epoxide based inhibitors of cysteine proteases
#271Acylated 4-amidino- and -4-guanidinobenzylamines for inhibition of plasma kallikrein
#272Pharmaceutical angiostatic dipeptide compositions and methods of use thereof
#273Lactams and uses thereof
#274Dipeptide derivatives
#275Selective dipeptide inhibitors of kallikrein
#276IAP binding compounds
#277Novel amide derivatives as growth hormone secretagogues
#278Compounds as inhibitors of hepatitis C virus NS3 serine protease
#279Process for producing dipeptides
#280Compounds as inhibitors of hepatitis C virus NS3 serine protease
#281Growth hormone secretagogues
#282Di-, tri-, and tetra-peptides having antiangiogenic activity
#283Dimeric small molecule potentiators of apoptosis
#284Growth hormone releasing peptides
#285Compounds and methods for treatment of thrombosis
#286Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels
#287STAT modulators
#288Amino acid derivatives, method for production thereof and pharmaceutical compositions comprising said derivative
#289Dipeptide phenyl ethers
#290Elastin peptide analogs and uses thereof
#291Elastin peptide analogs and uses thereof